logo
Amazon Stock: Buy, Hold or Sell?

Amazon Stock: Buy, Hold or Sell?

USA Today2 days ago

Amazon Stock: Buy, Hold or Sell? Amazon has the ingredients to keep growing for a while.
After touching a multi-year low of around $84 in early 2023, Amazon's (NASDAQ: AMZN) stock price has more than doubled to $200 (as of this writing), thanks to the improvement in financials.
As the company moves forward on tailwinds such as artificial intelligence (AI) and facing headwinds such as the e-commerce slowdown, investors may wonder: Is now the time to buy, hold, or sell Amazon stock?
Let's take a closer look.
How did Amazon perform in 2024?
First, a review of Amazon's recent performance, focusing on its 2024 performance. Overall, it was a solid year for several reasons.
Amazon expanded revenue by 11% to $638 billion, thanks to growth across all three major segments. North America was up by 10%, international was up by 9%, and Amazon Web Services (AWS) was up by 19%. While an 11% revenue growth rate is not unusually high, it is still remarkable considering the scale that Amazon operates in.
Moreover, while its top-line growth was solid, the highlight of Amazon's performance in 2024 was the massive improvements in its bottom line. Operating profit jumped 86% from $36.9 billion to $68.6 billion, due to profit growth across all segments. The rapid margin expansion demonstrates the giant's strong execution capabilities in managing its costs and the benefits of operating leverage.
Operationally, Amazon continued to improve delivery speeds, with more than 65% more items delivered to Prime members the same day or overnight than in the fourth quarter of 2023. It also launched Amazon Haul, a new ultra-low-price shopping service in the U.S., to compete against low-cost players like Temu and Shein.
Similarly, in its cloud computing business (AWS), the tech company delivered good progress in 2024, such as introducing its new Trainium2 AI chip, establishing its foundation models in Amazon Nova, and creating new models and features in Amazon Bedrock that give customers flexibility and cost savings. All these innovations help position the company in the ongoing AI race.
In other words, despite its size, the tech giant is still executing well to delight its users and maintain its share in key markets.
What are Amazon's prospects in the coming years?
Amazon might have become a household name thanks to the success of its e-commerce business, but the most significant growth drivers in the next few years will likely come from other segments.
The biggest winner will likely be AWS, which rides on megatrends like AI advancement and the ongoing migration to the cloud. For instance, the global AI market is expected to grow from $294 billion in 2024 to $1.772 billion by 2032, a compound average growth rate of 29%. As the most significant cloud computing player globally with a 30% market share, AWS is primed to benefit from this once-in-a-generation trend.
Another business gaining traction (which could accelerate further in the coming years) is Amazon's advertising business. Centered around Prime Video and Amazon Search, the advertising business generated $14 billion in revenue in the first quarter of 2025, up 18% year over year. This segment grew even faster than AWS (up 17% in the same quarter). Like AWS, advertising is a high-margin business, which will likely contribute to a margin expansion for the giant over time.
Unlike the previous two businesses, the e-commerce segment could see a mixed performance in the coming years. On the positive end, Amazon can leverage its massive scale to gain market share from traditional brick-and-mortar shopping and expand in emerging markets like India. The downside is that it has to deal with the uncertainties of tariffs and emerging competitors like Temu and Shein. So, while Amazon is still favorably positioned to grow its e-commerce business, the e-commerce prospects will not be as straightforward as those of AWS and the advertising business.
Still, while the prospects may differ for Amazon's various business segments, it is essential to highlight that the company has an unusual culture centered around its "Day 1" mentality. This mentality focuses on customer obsession, embracing new trends, willingness to experiment and fail, and avoiding bureaucracy.
As long as the company can maintain this culture, it is well-positioned to continue growing in the years to come, albeit at a slower pace, given its already enormous size.
Is Amazon's stock cheap?
Here's another factor that investors should consider before making a move in Amazon's stock: The stock valuation in relation to its past. Here, let's use price-to-sales (P/S) as a proxy.
Amazon's P/S ratio has ranged from 1.7 to 4.6 times in the last five years. As of this writing, it is 3.3 times, just around the middle of that range.
The current valuation suggests that while Amazon's stock is not a bargain today, it is not excessively priced compared to its past valuation.
What it means for investors
Amazon delivered strong results in 2024, highlighting the strength of its execution capabilities.
Its high-margin segments – AWS and advertising – will drive future growth, supported by trends like AI adoption. While e-commerce faces mixed prospects, Amazon's Day 1 culture will likely keep it competitive for the foreseeable future.
So, while the stock is not a screaming buy today, it is not a sell. Existing investors should hold on to the stock, while investors with a long-term horizon could consider buying a small position and adding to that position over time.
John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Lawrence Nga has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon. The Motley Fool has a disclosure policy.
The Motley Fool is a USA TODAY content partner offering financial news, analysis and commentary designed to help people take control of their financial lives. Its content is produced independently of USA TODAY.
Should you invest $1,000 in Amazon right now?
Offer from the Motley Fool: Before you buy stock in Amazon, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amazon wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you'd have $651,049!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you'd have $828,224!*
Now, it's worth notingStock Advisor's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you joinStock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share
Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share

Forbes

time6 minutes ago

  • Forbes

Amazon, A Small Pharmacy Player, Seeks To Dent CVS And Walgreens Medicare Share

Amazon Pharmacy is rolling out new features in hopes of attracting more seniors covered by Medicare's drug benefit, a potentially lucrative market dominated by CVS Health and Walgreens. In an announcement Tuesday, Amazon said it is launching a new 'caregiver support feature' that allows its customers to have someone else manage medications on their behalf. Once the caregivers are verified through a secure invitation, 'caregivers can now manage medications for their loved ones,' the company said. In addition, customers with Medicare Part D drug coverage can now access PillPack, Amazon's online pharmacy that is designed to simplify medication management, particularly for multiple prescriptions via pre-sorted and labeled packets delivered directly to patients' doors. It's the latest effort by the online retail giant Amazon to invest in its pharmacy business, which Drug Channels Institute estimates generated 'less than $2 billion in 2024 revenue - just 0.3% of the total prescription dispensing market.' Amazon doesn't disclose how many prescriptions it fills or financial information regarding its pharmacy and healthcare businesses. Amazon, which purchased PillPack seven years ago this month for more than $750 million, has yet to disclose revenues for its Amazon Pharmacy business in the parent company's quarterly earnings statements. In contrast, CVS filled 435 million prescriptions in the first quarter for an increase of 4.3% from the year ago period while Walgreens filled more than 309 million prescription in its most recent quarter, up 3.4%. Combined, Walgreens and CVS generated more than $370 billion in prescription revenues last year, According to Dryg Channels. CVS and Walgreens have the largest share of the U.S. prescription market by most measures at a combined 40% while Amazon's share is less than 1%, according to some studies. Neither CVS nor Walgreens would disclose how many Medicare Part D prescriptions the companies fill. By adding features for seniors, Amazon Pharmacy is looking to tap a Medicare prescription market growing by thousands every day. More than 11,000 Americans are turning 65 every day. Amazon is also trying to find a niche with Americans who are caring for an elderly family member. More than 50 million people in the U.S. 'are taking care of an aging family member,' Amazon said citing data from AARP. The aging population, coupled by industry statistics showing up to one-third of Americans don't take their medications as directed or never fill them. 'These updates deliver what our customers have been asking for—simpler medication management for themselves and their loved ones,' Amazon Pharmacy vice president John Love said. 'Whether you're a caregiver juggling multiple prescriptions for an aging parent, or a customer who could benefit from the convenience of pre-sorted packets delivered reliably each month, we're removing barriers and making pharmacy work better for you.'

Forklift Battery Market Size Expected to reach US$ 9.23 Billion by 2031, Experiences Growth Owing to Expansion of Warehousing and E-Commerce
Forklift Battery Market Size Expected to reach US$ 9.23 Billion by 2031, Experiences Growth Owing to Expansion of Warehousing and E-Commerce

Yahoo

time6 minutes ago

  • Yahoo

Forklift Battery Market Size Expected to reach US$ 9.23 Billion by 2031, Experiences Growth Owing to Expansion of Warehousing and E-Commerce

The global forklift battery market is experiencing steady growth, driven by increasing demand for electric forklifts across industries such as manufacturing, warehousing, logistics, and e-commerce. Valued at approximately USD 5.94 billion in 2024, the market is expected to grow at a CAGR of 6.6% through 2031. Key players in the market include EnerSys, Exide Technologies, East Penn Manufacturing, Crown Equipment Corporation, Trojan Battery Company, BYD, LG Chem, CATL, Samsung SDI, and A123 Systems. US & Canada, June 03, 2025 (GLOBE NEWSWIRE) -- According to a new comprehensive report from The Insight Partners, the global forklift battery market is observing significant growth owing to the shift toward electric forklift and rise in industrialization across the globe. The report runs an in-depth analysis of market trends, key players, and future opportunities. In general, the forklift battery market comprises a vast array of type, capacity, and application which are expected to register strength during the coming explore the valuable insights in the Forklift Battery Market report, you can easily download a sample PDF of the report – Overview of Report Findings Market Growth: The size was valued at US$ 5.94 billion in 2024 and is expected to reach US$ 9.23 billion by 2031; it is estimated to record a CAGR of 6.6% from 2025 to 2031. A forklift battery functions as a vital power source for forklifts and other industrial trucks, supplying the energy required for material handling tasks. These batteries are typically either lead-acid or lithium-ion (Li-ion), with Li-ion gaining preference due to advantages such as faster charging, longer service life, and lower environmental impact. The growing adoption of electric-powered forklifts—valued for their sustainability, lower maintenance, and cost-efficiency over internal combustion engine (ICE) models—has significantly increased the demand for forklift batteries. Expansion of Warehousing and E-Commerce: The e-commerce sector is experiencing robust growth, fueled by increasing internet and smartphone penetration, evolving consumer behavior, and technological innovation. Cross-border online shopping is also gaining traction as consumers look for unique products and competitive prices internationally. According to Eurostat, the share of companies in the EU adopting e-sales strategies rose from 17.21% in 2013 to 23.83% in 2023. To support this growth, many e-commerce companies are expanding their warehousing footprint across Europe. For instance, Amazon launched its first fulfillment center in the Netherlands in August 2023 to enable faster, localized order fulfillment. The boom in e-commerce has created a pressing need for clean, efficient material handling solutions, leading companies like Amazon and DHL to invest in fleets of battery-powered forklifts. Notably, in March 2022, DHL Supply Chain introduced autonomous forklifts at its multiuser warehouse in Bornem, Belgium, as part of its Accelerated Digitalization strategy. These robotic pallet movers enhance warehouse efficiency while reducing carbon emissions. As a result, the growing demand for automated and eco-friendly warehouse operations is significantly increasing the need for high-performance forklift batteries—particularly lithium-ion and lead-acid variants—to support continuous, round-the-clock logistics operations. Regional Overview: North America's forklift battery market is segmented into US, Canada, and Mexico. The North American forklift battery market, encompassing the US, Canada, and Mexico, is witnessing growth driven by increasing construction activity and rising commercial vehicle production. In the US, major automotive manufacturers such as Fiat Chrysler Automobiles, Ford, and General Motors are making substantial investments in commercial vehicle manufacturing. According to the American Automotive Policy Council (AAPC), the U.S. automotive sector contributed $2.64 trillion in value in 2021, accounting for 4.9% of the country's GDP and representing 6% of total manufacturing output. The demand for forklifts—and consequently forklift batteries—is further supported by significant investments in infrastructure. For example, in August 2021, the U.S. Ministry of Transportation and Infrastructure allocated $837 million for a highway expansion project between Alberta and British Columbia. Such projects, involving bridge construction and road expansion, require the use of construction vehicles like forklifts for efficient material handling. As a result, the ongoing development in infrastructure and commercial vehicle manufacturing is fueling the demand for high-performance forklift batteries across the region.. Geographical Insights: Asia Pacific dominated the forklift battery market in 2024. Europe is the second-largest contributor to the global forklift battery market, followed by North America. For Detailed Forklift Battery Market Insights, Visit: Market Segmentation Based on type, the market is segmented into lithium ion, lead acid, and others. The lead acid segment dominated the market in 2024. In terms of capacity, the market is segmented into 0-600 Ahr, 600-1200 Ahr, and above 1200 Ahr. The 0-600 Ahr segment held a larger share of the market in 2024. In terms of application, the forklift battery market is segmented into manufacturing, construction, warehouse & logistics, automotive, retail & wholesale stores, and others. The manufacturing segment dominated the market in 2024. Stay Updated on The Latest Forklift Battery Market Trends: Competitive Strategy and Development Key Players: Major companies operating in the forklift battery market include Accumulatorenwerke HOPPECKE Carl Zoellner & Sohn GmbH, Crown Equipment Corp, Exide Industries Ltd, EnerSys, East Penn Manufacturing Company, Contemporary Amperex Technology Co Ltd, TotalEnergies SE, Amara Raja Energy & Mobility Ltd, GS Yuasa Corp, leoch International Technology Limited Inc, TAB d.d., and BSL NEW ENERGY THCHENOLOGY CO., LTD. Trending Topics: Forklifts, lithium ion battery, pallet truck, and electric forklift trucks, among others Global Headlines "Exide Industries Ltd has invested an amount of INR 149.99 crore in Exide Energy Solutions through a rights issue. This capital infusion will support the establishment of Exide Energy Solutions' new lithium battery manufacturing facility in Bengaluru, addressing its diverse funding needs.' 'Amara Raja Advanced Cell Technologies Pvt. Ltd (ARACT), a wholly owned subsidiary of Amara Raja Energy & Mobility Ltd (ARE&M), one of India's leading battery manufacturers, has signed a technical licensing agreement with GIB EnergyX Slovakia s.r.o., a subsidiary of Gotion High-Tech Co Ltd. As part of the agreement, GIB EnergyX will license Gotion's world-class LFP technology for lithium-ion cells to ARACT." Purchase Premium Copy of Global Forklift Battery Market Size and Growth Report (2021-2031) at: Conclusion The rapid expansion of warehousing, driven by the growth of e-commerce and consumer goods sectors across multiple countries, is significantly boosting the demand for forklifts used in material handling operations. Electric forklifts, in particular, are well-suited for indoor environments such as warehouses and factories due to their clean, quiet, and efficient performance. The rise of e-commerce is fueled by greater access to high-speed internet, increased smartphone penetration, and the convenience of diverse payment options through various digital platforms. As a result, the global forklift battery market is experiencing growth, supported by the increasing pace of industrialization and a widespread shift toward electric-powered forklifts. However, market expansion is somewhat restrained by safety and operational challenges. Despite these hurdles, innovations in fast-charging technology and smart battery management systems are opening new avenues for manufacturers. Additionally, the growing adoption of Battery-as-a-Service (BaaS) models is emerging as a key trend, offering scalable and cost-effective solutions for end-users, and is expected to play a crucial role in shaping the market's future. The report from The Insight Partners, therefore, provides several stakeholders—including raw material/component providers, forklift battery manufacturers, forklift manufacturers, after-sales/service providers, and end users —with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities. Talk to Us Directly: Trending Related Reports: About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit Mathur E-mail: Phone: +1-646-491-9876 Press Release -

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

Associated Press

time8 minutes ago

  • Associated Press

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

WASHINGTON, June 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ('60 Degrees' or the 'Company'), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced results of an insurance claims analysis related to babesiosis and chronic fatigue, as conducted by Komodo Health, a healthcare technology company that delivers the evidentiary standard for real-world data and analytics, contracted by the Company. Results showed approximately 25,000 Americans seek reimbursement for babesiosis-related medical costs each year, according to 60 Degrees Pharmaceuticals. In contrast, current estimates published by the Centers for Disease Control and Prevention (CDC) show only 2,000 cases in 2020. Babesia infections last at least 12 months in 14 percent of patients and may relapse up to 27 months later, as documented in the scientific literature. Many physicians treating tick-borne infections speculate the true duration of infection may be much longer. The claims data indicated approximately 31 percent of babesiosis cases persist longer than 30 days, and that nearly half of those are associated with chronic fatigue lasting longer than six months. Fatigue is the last symptom of babesiosis to resolve in acute disease. Chronic fatigue during babesiosis has not been systematically described in the literature. Further, the claims data, which captured approximately 40 percent of U.S. diagnostic data, showed that over three years, more than 12 million U.S. adults experienced chronic fatigue greater than six months in duration. Current Infectious Diseases Society of America advice and other professional guidelines do not mandate babesiosis as a differential diagnosis if a patient self-reports experiencing such fatigue. The Company is testing, through its clinical development program, the medical hypothesis that the true burden of babesiosis is much larger than claims data suggest and is a function of the incidence of chronic fatigue lasting six months or longer, multiplied by the proportion of such individuals with confirmable infections. A molecular incidence study in patients with chronic fatigue commissioned by the Company was recently completed. Once published, the data will allow establishment of a ceiling on the incidence of persistent babesiosis. Clinical Babesiosis Studies Sponsored by 60 Degrees Pharmaceuticals Three 60 Degrees Pharmaceuticals-sponsored clinical trials ( NCT06478641, NCT06207370, NCT06656351 ) are underway or planned to evaluate tafenoquine's safety and efficacy in treating humans diagnosed with babesiosis. Data are expected from one or more of these studies in the first half of 2026 and will be used as part of a planned New Drug Application (NDA) submission to the U.S. Food and Drug Administration for babesiosis, anticipated in 2026. About ARAKODA® (tafenoquine) Tafenoquine was discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long terminal half-life of tafenoquine, which is approximately 16 days, offers the advantage of less frequent dosing for the prophylaxis of malaria. ARAKODA® is not suitable for everyone, and patients and prescribers should review the Important Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA® 2 x 100 mg tablets once per day for three days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months during travel, then 2 x 100 mg in the week following travel. ARAKODA® (tafenoquine) Important Safety Information ARAKODA® is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older. Contraindications ARAKODA® should not be administered to: Warnings and Precautions Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy. A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant's G6PD status before breastfeeding begins. Methemoglobinemia: Asymptomatic elevations in blood methemoglobin have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur. Psychiatric Effects: Serious psychotic adverse reactions have been observed in patients with a history of psychosis or schizophrenia, at doses different from the approved dose. If psychotic symptoms (hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and evaluation by a mental health professional as soon as possible. Hypersensitivity Reactions: Serious hypersensitivity reactions have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy. Delayed Adverse Reactions: Due to the long half-life of ARAKODA® (approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset and/or duration. Adverse Reactions: The most common adverse reactions (incidence greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase (ALT), motion sickness, insomnia, depression, abnormal dreams, and anxiety. Drug Interactions Avoid co-administration with drugs that are substrates of organic cation transporter-2 or multidrug and toxin extrusion transporters. Use in Specific Populations Lactation: Advise women not to breastfeed a G6PD-deficient infant or infant with unknown G6PD status during treatment and for 3 months after the last dose of ARAKODA®. To report SUSPECTED ADVERSE REACTIONS, contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088 or The full prescribing information of ARAKODA® is located here. About 60 Degrees Pharmaceuticals, Inc. 60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based Pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements. Cautionary Note Regarding Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the safeharbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ('SEC'), including the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC's website at As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Media Contacts: Sheila A. Burke [email protected] (484) 667-6330 Investor Contact: Patrick Gaynes [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store